These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34031488)

  • 1. Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p.
    Barbier RH; McCrea EM; Lee KY; Strope JD; Risdon EN; Price DK; Chau CH; Figg WD
    Sci Rep; 2021 May; 11(1):10765. PubMed ID: 34031488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
    Ylitalo EB; Thysell E; Thellenberg-Karlsson C; Lundholm M; Widmark A; Bergh A; Josefsson A; Brattsand M; Wikström P
    Prostate; 2020 Feb; 80(2):214-224. PubMed ID: 31799745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
    de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
    Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx.
    Sissung TM; Ley AM; Strope JD; McCrea EM; Beedie S; Peer CJ; Shukla S; van Velkinburgh J; Reece K; Troutman S; Campbell T; Fernandez E; Huang P; Smith J; Thakkar N; Venzon DJ; Brenner S; Lee W; Merino M; Luo J; Jager W; Price DK; Chau CH; Figg WD
    Mol Cancer Res; 2017 Aug; 15(8):1096-1105. PubMed ID: 28389619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy.
    Alsinnawi M; Zhang A; Bianchi-Frias D; Burns J; Cho E; Zhang X; Sowalsky A; Ye H; Slee AE; True L; Porter C; Taplin ME; Balk S; Nelson PS; Montgomery RB; Mostaghel EA
    Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):560-568. PubMed ID: 30890759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.
    Liu C; Armstrong CM; Lou W; Lombard A; Evans CP; Gao AC
    Mol Cancer Ther; 2017 Jan; 16(1):35-44. PubMed ID: 27794047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.
    Mostaghel EA; Marck BT; Plymate SR; Vessella RL; Balk S; Matsumoto AM; Nelson PS; Montgomery RB
    Clin Cancer Res; 2011 Sep; 17(18):5913-25. PubMed ID: 21807635
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Zhi L; Zhao L; Zhang X; Liu W; Gao B; Wang F; Wang X; Wang G
    Aging (Albany NY); 2021 Sep; 13(18):22164-22175. PubMed ID: 34526411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.
    Yang M; Xie W; Mostaghel E; Nakabayashi M; Werner L; Sun T; Pomerantz M; Freedman M; Ross R; Regan M; Sharifi N; Figg WD; Balk S; Brown M; Taplin ME; Oh WK; Lee GS; Kantoff PW
    J Clin Oncol; 2011 Jun; 29(18):2565-73. PubMed ID: 21606417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer.
    Armstrong CM; Liu C; Liu L; Yang JC; Lou W; Zhao R; Ning S; Lombard AP; Zhao J; D'Abronzo LS; Evans CP; Li PK; Gao AC
    Clin Cancer Res; 2020 Nov; 26(22):6064-6074. PubMed ID: 32928794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OATP1B3-1B7, a novel organic anion transporting polypeptide, is modulated by FXR ligands and transports bile acids.
    Malagnino V; Hussner J; Issa A; Midzic A; Meyer Zu Schwabedissen HE
    Am J Physiol Gastrointest Liver Physiol; 2019 Dec; 317(6):G751-G762. PubMed ID: 31509437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Emerging Role of the SLCO1B3 Protein in Cancer Resistance.
    Sun R; Ying Y; Tang Z; Liu T; Shi F; Li H; Guo T; Huang S; Lai R
    Protein Pept Lett; 2020; 27(1):17-29. PubMed ID: 31556849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-103a-2-5p/miR-30c-1-3p inhibits the progression of prostate cancer resistance to androgen ablation therapy via targeting androgen receptor variant 7.
    Chen W; Yao G; Zhou K
    J Cell Biochem; 2019 Aug; 120(8):14055-14064. PubMed ID: 30963631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KAT2A-mediated AR translocation into nucleus promotes abiraterone-resistance in castration-resistant prostate cancer.
    Lu D; Song Y; Yu Y; Wang D; Liu B; Chen L; Li X; Li Y; Cheng L; Lv F; Zhang P; Xing Y
    Cell Death Dis; 2021 Aug; 12(8):787. PubMed ID: 34381019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
    Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
    Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis.
    Li B; Jin X; Meng H; Hu B; Zhang T; Yu J; Chen S; Guo X; Wang W; Jiang W; Wang J
    Oncotarget; 2017 Jul; 8(29):47849-47860. PubMed ID: 28599307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AMP-activated protein kinase re-sensitizes A549 to paclitaxel via up-regulating solute carrier organic anion transporter family member 1B3 expression.
    Jiang S; Luo Y; Zhan Z; Tang Z; Zou J; Ying Y; Lin H; Huang D; Luo L
    Cell Signal; 2022 Mar; 91():110215. PubMed ID: 34920124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.
    Li Z; Alyamani M; Li J; Rogacki K; Abazeed M; Upadhyay SK; Balk SP; Taplin ME; Auchus RJ; Sharifi N
    Nature; 2016 May; 533(7604):547-51. PubMed ID: 27225130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.
    Gao S; Ye H; Gerrin S; Wang H; Sharma A; Chen S; Patnaik A; Sowalsky AG; Voznesensky O; Han W; Yu Z; Mostaghel EA; Nelson PS; Taplin ME; Balk SP; Cai C
    Clin Cancer Res; 2016 Jul; 22(14):3672-82. PubMed ID: 26936914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.
    Yu Z; Chen S; Sowalsky AG; Voznesensky OS; Mostaghel EA; Nelson PS; Cai C; Balk SP
    Clin Cancer Res; 2014 Mar; 20(6):1590-600. PubMed ID: 24449822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.